Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Rheumatoid Arthritis

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Rheumatology (Oxford)

Molina-Collada J, Otero-Varela L, Vela P, Manrique S, Erausquin C, Campos C, Manero J, Calvo J, Expósito L, García González J, Ruiz Montesinos MD, Rabadán E, Varela AM, Vilamajo IR, Colazo Burlato M, Plasencia C, Sánchez-Alonso F, Castrejón I, BIOBADASER Project Collaborative Group

doi: 10.1093/rheumatology/keaf556

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Rheumatology (Oxford)

Fujii T, Murata K, Nakabo S, Onishi A, Murakami K, Tanaka M, Morinobu A, Matsuda S

doi: 10.1093/rheumatology/keaf598

OsteoarthritisRheumatoid Arthritis

The Patient-Reported Outcomes Measurement Information System scale v1.2 Global Health (PROMIS-GH) is useful to assess mental and physical health in individuals with chronic musculoskeletal pain, rheumatoid arthritis, hip/knee osteoarthritis, or people undergoing physiotherapy: Results of factor and item response theory analyses

Arthritis Care Res (Hoboken)

Giusti EM, Pellicciari L, Crins MHP, Dekker P, van der Esch M, van der Leeden M, Lems WF, Dekker J, Boers M, van Schaardenburg D, Joly J, Verschueren P, Van der Elst K, Westhovens R, Terwee CB, Roorda LD

doi: 10.1002/acr.25674

Rheumatoid Arthritis

Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomised clinical trial

Rheumatology (Oxford)

Fadaei S, van der Leeuw MS, Linn-Rasker SP, de Klerk B, Peeters JJW, den Uyl D, Maas-de Kok A, Bos R, Tekstra J, Nap F, Marijnissen ACA, Welsing PMJ, van Laar JM

doi: 10.1093/rheumatology/keaf591

Related content

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomised clinical trial